Cerulean / Genentech Inc. / J.D. / M.B.A Interim / M.S. / D. / M.B.A. / /
Currency
USD / / /
Event
FDA Phase / /
Facility
Pipeline PRECLINICAL PHASE / /
IndustryTerm
oncology products / chemical hydrolysis / oncology product / biopharmaceutical / treatment for people living with cancer / marketed small molecule products / marketed products / /
MedicalCondition
tumor / cancer / commercially validated cancer / tumors / metastatic renal cell carcinoma / Blood Vessel Blood vessel cell NDC Released payload Tumor / advanced solid tumors / relapsed ovarian cancer / relapsed renal cell carcinoma / non-metastatic rectal cancer / once inside tumor / /
MedicalTreatment
chemotherapy / radiotherapy / /
Organization
GOG Foundation / Securities and Exchange Commission / /
Person
Pamela Strode / Christopher Guiffre / Alejandra Carvajal / Edward Garmey / Gregg Beloff / Marc Wolfgang / Scott Eliasof / / /
Position
Chief Financial Officer / Chief Medical Officer / Vice President / Clinical Operations / President / Vice President / General Counsel Tiffany Crowell Vice President / President & Chief Executive Officer / Vice President / Regulatory Affairs / Private / Vice President / General Counsel / Vice President / Research / M.D. Chief Medical Officer / /
The team at Cerulean (NASDAQ: CERU) is committed to improving treatment for people living with cancer. We apply our Dynamic Tumor Targeting™ Platform to create a portfolio of nanoparticle-drug conjugates (NDCs) designe